Rosetta Genomics Receives U.S. Patent for Treatment of Prostate Cancer

Further strengthens patent portfolio in molecular diagnostics and therapeutics in urologic cancers

PRINCETON, N.J. & REHOVOT, Israel--()--Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/446,505, titled “Compositions and Methods for the Prognosis and Treatment of Prostate Cancer.”

The patent claims the treatment of prostate cancer through the administration of anti-hsa-miR-210 or a sequence having 80% identity thereto, as well as a method for inhibiting the growth or viability of prostate cancer cells using anti-hsa-miR-210 or a sequence having 80% identity thereto.

In June 2014, the Company announced receipt of a separate Notice of Allowance from the USPTO for U.S. Patent Application No. 13/390,995, entitled ”Compositions and Methods for Prognosis and Treatment of Prostate Cancer,” which claims cover the expression of miR-205 as an indicator of good prognosis and relates to methods and kits for prognosis of prostate cancer.

“When issued, this new U.S. patent will fortify Rosetta Genomics’ leadership in microRNA technology and expand our footprint in urological cancers. Through our acquisition of PersonalizeDx, we offer FISH, IHC and PCR-based testing capabilities in urologic and other cancers, which provide content and platforms that complement our microRNA offerings to provide clinicians with valuable information to guide treatment decisions. This patent is important as this biomarker, over-expressed in primary prostate tumors, could be used as a therapeutic target for prostate cancer. We look forward to monetizing this new intellectual property,” noted Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. “We remain committed to strengthening and expanding our intellectual property portfolio to protect and broaden our ability to provide actionable genomic information when it matters most.”

About Prostate Cancer

Prostate cancer is the most common non-cutaneous cancer in males, with 1 of every 7 men being diagnosed during his lifetime, and is the second most common cause of cancer-related death in men in the United States. The American Cancer Society estimates that in 2014 about 233,000 new cases of prostate cancer will be diagnosed and about 29,480 men will die of prostate cancer.

About Rosetta Genomics

Rosetta develops and commercializes a broad range of microRNA-based and other high-value molecular diagnostics. Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Through the acquisition of PersonalizeDx, the Company also offers core FISH, IHC and PCR-based testing capabilities and partnerships in oncology and urology that provide additional content and platforms that complement the Rosetta offerings. Rosetta’s cancer testing services are commercially available through the Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs. For more information visit www.rosettagenomics.com.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta’s future expectations, plans and prospects including, but not limited to statements relating to Rosetta Genomics patent position and its strengthening, expansion and monetization of its intellectual property, as well as the importance of miR-210 in prostate cancer, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2014 as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Contacts

Company:
Rosetta Genomics
Ken Berlin, 609-419-9003
President & CEO
investors@rosettagenomics.com
or
Investors:
LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com

Contacts

Company:
Rosetta Genomics
Ken Berlin, 609-419-9003
President & CEO
investors@rosettagenomics.com
or
Investors:
LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com